22nd Century Group Inc's Stock Drops 12.26%, but Shows Recent Recovery

Business by 2FIRSTS.ai
Dec.06.2023
22nd Century Group Inc's Stock Drops 12.26%, but Shows Recent Recovery
22nd Century Group Inc's stock price fell 12.26% from its previous closing price of 0.26, despite a 10.19% increase in the past five trading days.

According to a report by Zacks Investment Research, the stock price of 22nd Century Group Inc (NASDAQ: XXII) has dropped by 12.26 percentage points, closing at 0.26 below its previous closing price.

 

Despite this, the company's stock price has risen by 10.19% over the past five trading days. The VLN tobacco products of 22nd Century Group have been certified by the US FDA as reduced-risk tobacco products for the first time.

 

The question of whether the stock of 22nd Century Group Inc. (NASDAQ: XXII) is worth investing in has received mixed market reactions. The company's stock has experienced a 10.19% increase over the past week, but has seen declines of 50.64% and 84.90% over the past 30 days and 90 days respectively.

 

The performance of 22nd Century Group Inc. (NASDAQ: XXII) in recent times has been unable to surpass its 52-week low, resulting in the company sustaining a loss of -98.77% over a period of time. However, in the past five trading days, the stock has shown some recovery, reaching a gain of +10.19%. Nonetheless, it has still dropped by 98.43% compared to the 200-day moving average of 0.3131 USD.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S. FDA posts TPSAC meeting materials ahead of discussion on ZYN MRTP applications
U.S. FDA posts TPSAC meeting materials ahead of discussion on ZYN MRTP applications
On January 20, 2026, the U.S. Food and Drug Administration (FDA) posted meeting materials ahead of a virtual Tobacco Products Scientific Advisory Committee (TPSAC) meeting scheduled for January 22, 2026, to discuss modified risk tobacco product (MRTP) applications submitted by Swedish Match USA, Inc. for 20 ZYN nicotine pouch products.
Jan.21 by 2FIRSTS.ai
Product | INNOKIN Launches Magnetic Open-System Device, Pod + Power Bank Design Debuts in UK and US Channels
Product | INNOKIN Launches Magnetic Open-System Device, Pod + Power Bank Design Debuts in UK and US Channels
INNOKIN has recently launched its new open-system e-cigarette, EZ LEVA, on its official website, and it is now available through online channels in the UK and the United States. Featuring a magnetic design, the device adopts a pod + power bank form factor. Its 400mAh (device) + 2000mAh (charging case) battery setup follows a similar configuration logic to comparable products such as the SMOK Airmate and KIWI 2.
Dec.09 by 2FIRSTS.ai
Survey Shows E-cigarette Use Doubles Among Young Thais
Survey Shows E-cigarette Use Doubles Among Young Thais
Thailand’s latest national health survey shows a sharp increase in e-cigarette use among people under 30, particularly among female adolescents. Researchers found that vaping has not reduced overall tobacco harm and has instead driven growth in new nicotine users, with younger ages of initiation. Public health experts urged sustained enforcement and comprehensive policies centred on banning e-cigarettes, strengthening law enforcement and expanding public awareness to protect children and youth.
Dec.19 by 2FIRSTS.ai
FDA Rolls Out Online PMTA Platform, a Move That 2Firsts Analysts Say Could Pull Grey-Market Products Toward Formal Compliance
FDA Rolls Out Online PMTA Platform, a Move That 2Firsts Analysts Say Could Pull Grey-Market Products Toward Formal Compliance
FDA’s launch of a web-based PMTA system signals faster reviews and, 2Firsts experts say, a possible inflection point for the U.S. e-cigarette market’s shift out of the grey zone.
Dec.04
Russia proposes extending voluntary labeling pilot for reusable e-cigarettes to Aug. 31, 2026
Russia proposes extending voluntary labeling pilot for reusable e-cigarettes to Aug. 31, 2026
Russia’s Ministry of Industry and Trade has proposed extending a voluntary labeling pilot covering reusable e-cigarettes and similar personal electric vaporizing devices until August 31, 2026. A draft government decree has been published on the unified portal for posting drafts of normative legal acts.
Jan.22 by 2FIRSTS.ai
Philippine FDA Requires Licenses for Vape Products with Medical Claims
Philippine FDA Requires Licenses for Vape Products with Medical Claims
The Philippine Food and Drug Administration has announced that establishments selling vaporized nicotine and non-nicotine products and novel tobacco products with medicinal or therapeutic claims must secure Licenses to Operate. Such products are also required to be registered as pharmaceutical products through the Center for Drug Regulation and Research. The FDA urged stakeholders to comply with the new requirements to ensure product safety, efficacy and quality.
Dec.22 by 2FIRSTS.ai